scholarly journals Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19

Author(s):  
Anthony V. Incognito ◽  
Philip J. Millar ◽  
W. Glen Pyle

Acute respiratory distress syndrome and subsequent respiratory failure remains the leading cause of death (>80%) in patients severely impacted by COVID-19. The lack of clinically effective therapies for COVID-19 calls for the consideration of novel adjunct therapeutic approaches. Though novel antiviral treatments and vaccination hold promise in control and prevention of early disease, it is noteworthy that in severe cases of COVID-19, addressing "run-away" inflammatory cascades are likely more relevant for improvement of clinical outcomes. Viral loads may decrease in severe, end-stage coronavirus cases, but a systemically damaging cytokine storm persists and mediates multiple organ injury. Remote ischemic conditioning (RIC) of the limbs has shown potential in recent years to protect the lungs and other organs against pathological conditions similar to that observed in COVID-19. We review the efficacy of RIC in protecting the lungs against acute injury and current points of consideration. The beneficial effects of RIC on lung injury along with other related cardiovascular complications are discussed, as are the limitations presented by sex and ageing. This adjunct therapy is highly feasible, non-invasive, and proven to be safe in clinical conditions. If proven effective in clinical trials for acute respiratory distress syndrome and COVID-19, application in the clinical setting could be immediately implemented to improve outcomes.

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Zeshan Ali

In December 2019, a novel virus was discovered in China causing severe acute respiratory distress syndrome and the virus was designated as SARS-CoV-2 [1]. On 11th March 2020, the Corona Virus (SARS-CoV-2) was declared a pandemic by World Health Organization (WHO) [2]. Millions of people worldwide have been affected by this virus [3]. Most of the patients shows mild symptoms. Severe cases lead to the death of patients due to severe respiratory failure. Multiple organ failure has been seen in many patients suffering from COVID-19


2015 ◽  
Vol 20 (3) ◽  
pp. 36-46
Author(s):  
M. G Avdeeva ◽  
V. N Gorodin ◽  
M. G Pronin

The purpose of the study The improvement the diagnosis and prognosis of the course of leptospirosis on the basis of the study of characteristics of clinical picture and pathomorphogenesis, determination of the main causes of lethal outcomes at different stages of the disease, in dependence on the level of the management of specialized medical care. Materials and methods There were analyzed medical records and autopsy protocols of 168 patients who died from leptospirosis in the Krasnodar region in 1969-2014 and medical records of 125 patients with both severe course of leptospirosis and the development of multiple organ insufficiency. 4 groups were considered: 1st -patients died in 1969-1988 before applying of efferent methods therapy, 86 lethal cases; 2nd - patients died in 1989-1997, application of hemosorption and hemofiltration, 31 cases; 3rd - 1998-2008, the use of plasmapheresis and immunocorrectors, 33 cases; 4-th group of 18 patients who died in 2009-2014, up-to-date medical assistance. There was studied autopsy material in 55 patients. The etiological role of L.icterohaemorrhagiae was proved in 75% of lethal cases, L.grippotyphosa - in 16.7%, L.sejroe (Mus 24) - in 8.3%. The results of the study In the initial period at the 3-5 days of illness life-threatening events are toxic shock and hemorrhagic syndrome. In the period of the height of disease (2-3 weeks) polyorganic failure in form of acute renal and hepatic insufficiency , and also combination of hemorrhagic syndrome with acute respiratory distress syndrome assume a great significance Starting From the 4th week, the first place in the risk of the development of the unfavorable outcome is occupied by secondary bacterial complications, sepsis and septic shock. Pathomorphological changes at leptospirosis correspond to organ-system lesions typical for Systemic inflammatory response syndrome - SIRS . Multiple organ dysfunction formed in the height of leptospirosis is a consequence not only of the alternative effect of leptospira and its toxins, but the result of immunopathological reactions of systemic inflammation. At the present time of the observation the lethal outcome occurs in average on the 17,9±2,30 day of illness, the average patient day in reanimation unit is prolonged up to 11,2±2,43. DIC and acute respiratory distress syndrome as a components of multiple organ failure, and at the later stages of the disease - pneumonia and sepsis, indicate to the negative forecast. Risk factors for the unfavorable outcome include late hospitalization and the increased percentage of comorbidity (61%). For the determination of the severity and the prognosis of the course of the disease it is worth to use SIRS criteria and Sepsisrelated Organ Failure (SOFA) rating scale of organ dysfunction. The development of lethal outcome with a probability of 70% is determined in cases with the failure of 4 or more functional systems. The total Score on a SOFA scale in lethal outcomes is 18.7 scores at the first week of illness, and 14.5 scores at the 5-6th weeks. Conclusion The main causes of lethal outcomes leptospirosis are determined by the stage of pathogenesis, depend of the stage of the disease and methods of therapy. The treatment of patients with leptospirosis should be carried out in specialized infectious hospitals with ICUs equipped for efferent methods of detoxification.


Author(s):  
Горбачёва ◽  
Svetlana Gorbacheva ◽  
Дац ◽  
Andrey Dats ◽  
Дац ◽  
...  

We studied the effect of furosemide application at the pre-hospital stage on survival rate and mortality risk in patients with acute respiratory distress syndrome. It was found that out of 665 patients admitted to intensive care units, 90 have been diagnosed with acute respiratory distress syndrome, of which 75 have noted decreased preload. Those patients were divided into two groups: group 1 (n = 28) received furosemide on the first day, group 2 (n = 47) did not receive furosemide. The patients of both groups matched by age, the severity of the condition and the severity of organ dysfunction. The 10-day survival rate in the patients with acute respiratory distress syndrome and reduced preload received furosemide at the pre-hospital stage made 11 % and was significantly lower than in the patients without furosemide– 43 % (p = 0.031). The frequency of multiple organ dysfunction syndrome in group 1 the was statistically higher than in patients without furosemide (93 % and 75 % respectively; p = 0.048). Furosemide admin-istration in patients with acute respiratory distress syndrome and reduced preload 1.8 times increases the relative mortality risk (p = 0.032).


Sign in / Sign up

Export Citation Format

Share Document